Clinical trial NCT01269866: Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus
Official title: Duloxetine (Cymbalta) in the Reduction of Pain Severity in Patient With Systemic Lupus Erythematosus: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Systemic Lupus Erythematosus
Keywords: Lupus Pain
Lupus
Pain
Systemic Lupus Erythematosus
Duloxetine
Cymbalta
Lead sponsor: Brain Resource Center
Sponsor class: OTHER
First posted: 2011-01-04
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Duloxetine (cymbalta) can reduce pain severity in patient with Systemic Lupus Erythematosus.

Detailed description: Duloxetine (Cymbalta) is a reuptake inhibitor of both serotonin and norepinephrine. By increasing levels of serotonin and norepinephrine, the descending inhibitory pain pathways may function better. These pathways lessen the perception of pain. Results of double blind, placebo controlled, clinical trials investigating the effectiveness of Duloxetine (Cymbalta) have shown that at doses of 60 mg once a day or 60 mg twice a day, Duloxetine (Cymbalta) demonstrated significantly higher rates of treatment response for pain when compared to placebo.

Given the positive findings in other clinical trial studies for Duloxetine (Cymbalta) such as Diabetic Peripheral Neuropathy (Raskin et al., 2005) and Fibromyalgia (e.g. Arnold et al., 2005), the investigators hypothesize that Duloxetine (Cymbalta) may reduce the pain severity, frequency and intensity of exacerbations in patients with SLE.

Eligibility criteria: Inclusion Criteria:

1. A diagnosis of Systemic Lupus Erythematosus (SLE) according to the American College of Rheumatology (ACR) classification criteria, before visit 1.
2. Able to swallow all required medication without opening or crushing.
3. Male or female outpatient 18-65 years old at visit 1.
4. Painful physical symptoms with a frequency \> or equal to 2 times per week.
5. Painful physical symptoms with a score \> or equal to 4 on the BPI- SF average pain question at visits 1 and 2.
6. Clinical Global Impression of Severity (CGI-S) score 3 or higher at visit 1.
7. Able to speak, read and provide informed consent.
8. Judged by the investigator to be reliable and agree to keep all appointments.

Exclusion Criteria:

1. Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit.
2. Pregnancy, nursing. Women of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopausal) who are not using a medically accepted means of contraception (For example, oral contraceptive, contraceptive patch, implant, Depo-Provera®, Norplant®, reliable barrier method/devices \[diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices\]
3. Positive urine drug screen for any substance of abuse. Note: If the subject has a positive drug screen for a substance at Visit 1, a retest may be performed prior to Visit 2 if, in the judgment of the investigator, there is an acceptable explanation for the positive result. A retest is not required for a positive result for benzodiazepines or hypnotics if the investigator confirms use is within protocol criteria.
4. Serious medical illness, including any cardiovascular, hepatic, renal respiratory hematologic, endocrinologic or neurologic disease, or significant laboratory abnormality as judged by investigator.
5. Substance/alcohol abuse or dependency in the last 6 months.
6. History of serious suicide attempt or subject judged clinically to be at serious suicidal risk in the opinion of the investigator.
7. Uncontrolled narrow angle glaucoma.
8. Known hypersensitivity to Duloxetine or any active ingredients.
9. Treatment with a MAOI within 14 days prior to Visit 2 or have the potential need to use an MAOI during the study or within 5 days of discontinuation of study drug. (See Concomitant Medication List)
10. Have epilepsy or history of seizure disorder.
11. Use of any of the prohibited medications including thioridazine (Mellaril), or all the potent CYP1A2 inhibitors, that use of these drugs are excluded.

Primary outcomes:
measure: Changes in the Brief Pan Inventory average pain questionnaire
timeFrame: Up to 8 weeks
Secondary outcomes:
measure: 1. Change in Patient Global Impression of Improvement (PGI-I) score 2. Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score. 3. Change in Clinician Global of Impression (CGI) score
timeFrame: Up to 8 weeks
Other outcomes:
Locations:
city: New york
country: United States
facility: Brain Resource Center
state: New York
Study officials:
affiliation: Brain Resouce Center
name: Jesus Gutierrez Stone, MD
role: PRINCIPAL_INVESTIGATOR
References: